New drug ziltivekimab tested for kidney disease inflammation
NCT ID NCT05379829
First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This early-stage trial studied how ziltivekimab works in the body of 24 Chinese adults with chronic kidney disease and signs of inflammation. Participants received either the drug or a placebo as three injections over several weeks. The study measured drug levels and safety, with results expected to guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE AND SYSTEMIC INFLAMMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
-
Chinses People's Liberation Army General Hospital-Nephrology
Beijing, Beijing Municipality, 100853, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Soochow University-Endocrinology
Suzhou, Jiangsu, 215006, China
-
Zhongda Hospital Southeast University-Nephrology
Nanjing, Jiangsu, 210009, China
-
Zhongda Hospital Southeast University-Neurology
Nanjing, Jiangsu, 210009, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ziltivekimab
What this could lead to
If successful, this could point toward a treatment that reduces inflammation in people with chronic kidney disease.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so results may not apply to larger populations. The drug may not show meaningful benefits or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.